Clinical study of Rituximab for inhibition of antibody mediated rejection in ABO-incompatible kidney transplantatio
Phase 3
- Conditions
- Chronic kidney disease patient to whom ABO incompatibility kidney transplantation is planned.
- Registration Number
- JPRN-UMIN000006635
- Lead Sponsor
- Zenyaku Kogyo Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
Not provided
Exclusion Criteria
1) pregnant woman or lactating mothers 2) positive HBV serology(i.e., HBs antigen, HBs and/or HBc antibody), and positive HCV antibody 3) HIV infection 4) HTLV-1 infection 5) active infection of any kind
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of humoral rejection mediated by anti-ABO antibody, which may occur within 4 weeks after transplantation.
- Secondary Outcome Measures
Name Time Method 1) 1-year graft survival 2) 1-year patient survival 3) 1-year incidence of rejection reaction